Mariner
FULC icon

Mariner’s Fulcrum Therapeutics FULC Stock Holding History

Mariner’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
28,104
+4,844
+21% +$29.5K ﹤0.01% 3326
2026
Q1 		$178K Buy
+23,260
New +$216K ﹤0.01% 3197
2025
Q1 		– Sell
-16,516
Closed -$77.6K – 3502
2024
Q4 		$77.6K Buy
+16,516
New +$60.9K ﹤0.01% 3228

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mariner's FULC Position: Q2 2026 in Review

Mariner increased its Fulcrum Therapeutics (FULC) stake by 21% in Q2 2026, buying an estimated $29.5K and bringing the position to 28,104 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3326.

Mariner first reported a position in FULC in Q4 2024 and has held it in 3 quarters since. The position peaked at $178K in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Mariner held 28,104 shares of Fulcrum Therapeutics worth $103K as of Q2 2026.
  • Mariner bought 4,844 Fulcrum Therapeutics shares in Q2 2026, an estimated $29.5K.
  • Fulcrum Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3326 holding.
  • Mariner first reported a position in Fulcrum Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Mariner's Fulcrum Therapeutics position peaked at $178K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.